---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092520"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:47:30.370528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026

## Summary
- Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.
- FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.
- Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.
- Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.
- CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026.

## SEC filing metadata
- accession: 0001193125-26-092520
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/0001193125-26-092520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/clym-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092520
- JSON: https://secwatch.observer/filing/0001193125-26-092520.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092520.txt

## Key facts
- Earnings Releases
  Climb Bio, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
  - Period: fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/0001193125-26-092520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.